TY - JOUR T1 - Venous thromboembolism in lung cancer with clinical analysis of 89 cases JF - European Respiratory Journal JO - Eur Respir J VL - 40 IS - Suppl 56 SP - P3887 AU - Ren Zhu AU - Jinming Liu Y1 - 2012/09/01 UR - http://erj.ersjournals.com/content/40/Suppl_56/P3887.abstract N2 - Objective: The aim of this study was to investigate the associated clinical factors and to provide evidences for prevention and therapies of VTE in lung cancer patients.Methods: We retrospectively reviewed the clinical data of 2,053 lung cancer patients with definite diagnosis by cytology or pathology between July 2008 and June 2010 at Shanghai Pulmonary Hospital.Results: In 2 ,053 lung cancer patients, 89 were confirmed with VTE. The incidence rate of VTE in Adenocarcinoma patients and non-adenocarcinoma patients was 5.65% and 3.02%. The incidence rate of VTE in StageI∼IIIa lung cancer patients was significantly decrease (1.48%) in comparison to that in stage IIIb∼IV patients (5.74%). Significant difference of incidence rate of VTE was showed in the patients with or without comorbidities (2.70% and 6.73%; P<0.01). The incidence rate of VTE in pretherapy lung cancer patients with normal value of platelet count, D-dimer, IL-1 and TNF was 3.72%,0.31%,2.44%,3.27%, respectively, whereas, the rate in pretherapy lung cancer patients with high value was 6.26%,19.91%, 10.26%, 7.74% respectively(P<0.05). There were no relations between other clinical factors and the incidence of VTE. Logistic analysis showed adenocarcinoma, comorbidities, high value of D-dimer, IL-1, TNF in blood were the related important factors with increased VTE incidence.Conclusions: Adenocarcinoma is the most common pathological type in lung cancer patients with VTE. The high risk factors of VTE include comorbidities and increase of D-dimer, IL-1 and TNF in blood. Close attention should be paid to those lung cancer patients with high risk factors of VTE. ER -